US · 1 sources covering this

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

Fox NewsRight·1h ago
FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails.
Read at Fox News →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/5d89e47e41a462255680a22cfa5fb9d77f57ebf2"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double"></iframe>

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

How 1 sources are covering this

FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double

More from US

Hundreds missing, including 47 Americans, in deadly Nepal floods, local officials say

Nvidia projects 70% revenue growth in 2028

Arizona State hockey player, Blues draft pick hospitalized after collapsing during training

Meta settles social media addiction suit for up to $17.1 billion

Reader

Trust & legal

Across the network